Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2664 results

Media Release / Sep 15, 2023
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
Media Release / Sep 06, 2023
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase…
Key Release / Oct 04, 2023
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and…
Media Release / Oct 05, 2023
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy…
Key Release / Oct 02, 2023
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria…
Media Release / Sep 26, 2023
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from…
Media Release / Sep 25, 2023
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…
Media Release / Sep 18, 2023
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
Media Release / Oct 20, 2023
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors,…
Media Release / Oct 23, 2023
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated…

‹ Previous page
1
…
55
56
57
58
59
60
61
…
267
› Next page